0001104659-19-057011.txt : 20191029 0001104659-19-057011.hdr.sgml : 20191029 20191028181634 ACCESSION NUMBER: 0001104659-19-057011 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20191029 DATE AS OF CHANGE: 20191028 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEUROONE MEDICAL TECHNOLOGIES Corp CENTRAL INDEX KEY: 0001500198 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 270863354 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-87476 FILM NUMBER: 191174087 BUSINESS ADDRESS: STREET 1: 7599 ANAGRAM DR CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 BUSINESS PHONE: (952) 426-1383 MAIL ADDRESS: STREET 1: 7599 ANAGRAM DR CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 FORMER COMPANY: FORMER CONFORMED NAME: Original Source Entertainment, Inc. DATE OF NAME CHANGE: 20100830 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Fredrickson Wade CENTRAL INDEX KEY: 0001709644 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 10006 LIATRIS LANE CITY: EDEN PRAIRIE STATE: MN ZIP: 55347 SC 13D/A 1 tm1921299d1_sc13da1.htm SC 13D/A

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13D/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

 

NeuroOne Medical Technologies Corporation

(Name of Issuer)

 

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

64130M 100

(CUSIP Number)

 

 

Wade Fredrickson

4825 Suburban Drive

Shorewood, MN 55331

(612) 940-2771

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

October 21, 2019

(Date of Event Which Requires Filing of this Statement)

  

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 64130M 100

1

NAME OF REPORTING PERSON:

 

Wade Fredrickson

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a) ¨

(b) ¨

3 SEC USE ONLY:
4

SOURCE OF FUNDS:

 

PF

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e):

¨

6

CITIZENSHIP OR PLACE OF ORGANIZATION:

 

United States 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
7

SOLE VOTING POWER:

 

2,113,459* 

8

SHARED VOTING POWER:

 

9

SOLE DISPOSITIVE POWER:

 

2,113,459* 

10

SHARED DISPOSITIVE POWER:

 

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

2,113,459* 

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 ¨

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

 

15.7%* (See Item 5 herein) 

14

TYPE OF REPORTING PERSON:

 

IN 

 

* This is an amended Number.

 

END OF COVER PAGE

 

 2 

 

 

CUSIP No. 64130M 100 Page 3 of 4

 

This Amendment No. 2 amends the Schedule 13D dated July 20, 2017, as amended by the Schedule 13D/A dated March 1, 2018 (as amended, the “Schedule 13D”) of Wade Fredrickson, an individual, in respect of shares of common stock, par value $0.001 per share (the “Common Stock”), of NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Issuer”), as follows (unless otherwise indicated, all capitalized terms used but not defined herein have the meaning ascribed to such terms in the Schedule 13D):

 

Item 5. Interest in Securities of the Issuer. Item 5(a), (b) and (c) are hereby amended to read in their entirety as follows:

 

(a) – (b)

 

           

(b)

Number of Shares as to which the person has:

 

 

Name

 

(a)

Amount Beneficially Owned

 

(a)

Percent of Class*

  Sole Power to Vote or to Direct the Vote   Shared Power to Vote or to Direct the Vote   Sole Power to Dispose or to Direct the Disposition   Shared Power to Dispose or to Direct the Disposition
Wade Fredrickson   2,113,459   15.7%   2,113,459   0   2,113,459   0

 

* Based on 13,490,204 shares of Common Stock outstanding as of August 9, 2019 was 13,490,204 as represented in the Issuer Form 10Q for the period ended June 30, 2019.

 

(c)Except for the transactions described in Item 6 of this Schedule 13D, during the last sixty days there were no transactions with respect to the Common Stock effected by Mr. Fredrickson.

 

Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Item 6 is hereby amended to read in its entirety as follows:

 

As of October 21, 2019, Mr. Fredrickson sold an aggregate of 500,000 shares of Common Stock to six unrelated purchasers, Dr. Faisal Siddiqui, Anish Monga, Sean Wambold, Mustafa Ameenuddin, Haider Akmal, and RTI Consulting LLC, pursuant to six, privately-negotiated, transactions.

 

On October 21, 2019, Mr. Fredrickson entered into a lock-up agreement (the “Lock-Up Agreement”) with the Issuer in which he agreed, subject to certain exceptions, not to offer, sell, transfer or otherwise dispose of the Issuer’s securities for a period of 18 months following the effective date of the Agreement.

 

Except as described above, to the knowledge of Mr. Fredrickson, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, among the person named in Item 2 or between such person and any other person, with respect to any securities of the Issuer, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

 

Item 7.Material to be Filed as Exhibits. Item 7 is hereby amended to add an Exhibit 3 thereto as follows:

 

Exhibit 3 Lock-Up Agreement dated October 21, 2019

  

 

 

 

CUSIP No. 64130M 100 Page 4 of 4

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: October 21, 2019

 

WADE FREDRICKSON

 

 

/s/ Wade Fredrickson                           

Wade Fredrickson, individually

 

 

 

 

EX-99.3 2 tm1921299d1_ex-3.htm EXHIBIT 3

Exhibit 3

 

 

Lock-Up Agreement

 

LOCK-UP AGREEMENT

 

This Lock-up Agreement (this “Agreement”) is made effective as of October 21, 2019 (the “Effective Date”) by and between Wade Fredrickson (“Shareholder”) and NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”). Shareholder and the Company are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. Capitalized terms used and not otherwise defined in this Agreement shall have the respective meanings given to them in the Stock Sale Agreement (as defined below).

 

Recitals

 

Whereas, Shareholder and certain purchasers desire to enter into that certain Stock Sale Agreement of even date herewith (the “Stock Sale Agreement”) pursuant to which Shareholder will sell shares of the Company’s common stock to certain purchasers (the “Purchasers”);

 

Whereas, following the completion of the Closing of the Stock Sale Agreement, Shareholder will beneficially own 2,113,459 shares of the Company’s common stock (the “Retained Shares”); and

 

Whereas, as a material inducement and a condition to the transactions contemplated by the Stock Sale Agreement, the Company and the Purchasers have requested that the Company and Shareholder enter into this Agreement.

 

Agreement

 

Now, Therefore, in consideration of the foregoing recitals and the mutual promises and covenants herein contained, and for other good and valuable consideration the receipt of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1.                  Restrictions on Transfer.

 

(a)               Lock-up. Shareholder hereby agrees that Shareholder will not, subject to the exceptions set forth in this Agreement, during the period commencing on the Effective Date and ending on eighteen (18) month anniversary of the Effective Date (the “Lock-up Period”), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Company’s common stock (including, for clarity, any of the Retained Shares), or any securities convertible into or exercisable or exchangeable for the Company’s common stock, including without limitation, such other securities which may be deemed to be beneficially owned by Shareholder (or any interest therein, including without limitation, any transfer of Shareholder’s equity interests) in accordance with the rules and regulations of the SEC (collectively, the “Lock-up Securities”) or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of shares of the Company’s common stock or such other securities, whether any such transaction described in clause (i) or (ii) of this Section 1(a) (each, a “Transfer”) is to be settled by delivery of shares of the Company’s common stock or such other securities, in cash or otherwise. As used in this Agreement, “beneficially own” or “beneficial ownership” with respect to any securities means having “beneficial ownership” of such securities as determined pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as the same may be amended (the “Exchange Act”).

 

 1 

 

 

(b)              Legends/Stop Orders. Shareholder acknowledges and agrees that the Company shall be entitled to place legends on the certificates or book entry account representing any of the Lock-up Securities and/or stop orders with the transfer agent of the Company with respect to any of the Lock-up Securities. Upon the release of any of the Lock-up Securities from this Agreement, the Company will reasonably cooperate with Shareholder to facilitate the timely preparation and delivery of certificates or evidence of the book entry account representing the Lock-up Securities without such restrictive legend described above or the withdrawal of any stop transfer instructions. Shareholder acknowledges and agrees that the Company may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or book entry account or other documents or instruments evidencing ownership of the Lock-up Securities:

 

THE SHARES REPRESENTED BY THIS CERTIFICATE/BOOK ENTRY ACCOUNT ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

(c)               Additional Acknowledgments. Shareholder understands that each of the Purchasers and the Company is relying upon this Agreement in proceeding toward consummation of the transactions contemplated by the Stock Sale Agreement. Shareholder further understands that this Agreement is irrevocable. An attempted transfer in violation of this Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Agreement, and will not be recorded on the stock transfer books of the Company. Shareholder acknowledges and agrees that any underwriter of the Company’s securities during the Lock-Up Period is entitled to rely on Shareholder’s covenants contained in this Agreement and is an intended third party beneficiary of the terms and conditions of this Agreement.

 

2.                  Exceptions to lock-up. Notwithstanding the provisions of Section 1(a), during the Lock-Up Period, Shareholder may Transfer all or a portion of the Locked-Up Shares:

 

(a)               To the Purchasers at each Closing (as defined in the Stock Sale Agreement) pursuant to the terms and conditions of the Stock Sale Agreement;

 

(b)              As a bona fide gift or gifts, provided that the donee or donees thereof agree in writing, in form and substance reasonably satisfactory to the Company, to be bound by the terms and conditions of this Agreement;

 

(c)               To any trust for the direct or indirect benefit of Shareholder or an immediate family member of Shareholder, provided that the trustee of the trust agrees in writing, in form and substance reasonably satisfactory to the Company, to be bound by the terms and conditions of this Agreement;

 

 2 

 

 

(d)              To Shareholder’s affiliates (including, if applicable, commonly controlled or managed investment funds) provided that such affiliate(s) agree in writing, in form and substance reasonably satisfactory to the Company, to be bound by the terms and conditions of this Agreement;

 

(e)               Pursuant to a tender or exchange offer publicly recommended by the Company’s board of directors;

 

(f)                Pursuant to a merger, stock sale, consolidation or other transaction publicly recommended by the Company’s board of directors;

 

(g)               By will or other testamentary document or by intestacy;

 

(h)              Commencing six (6) months after the Effective Date, to any third party or parties, including a disposition for value, provided that such third party or parties agree(s) in writing, in form and substance reasonably satisfactory to the Company, to be bound by the terms and conditions of this Agreement, and provided further that each such third party or parties shall be deemed not to be an underwriter of the Locked-Up Shares so sold within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”);

 

(i)                 Commencing six (6) months after the Effective Date, to any third party in a transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(4) thereof, an amount of the Locked-Up Shares equal to or less than 1% of the average weekly reported volume of trading of the Company’s common stock on all national securities exchanges and/or reported through the automated quotation system of a registered securities association during the four calendar weeks preceding the date of receipt of the order to execute the transaction by the broker or the date of execution of the transaction directly with a market maker; and/or

 

(j)                Pursuant to and to the extent the Company grants an exception to the lock-up provisions of any other person subject to a lock-up agreement with it, the Company shall provide a substantially similar exception to Shareholder hereunder; and/or

 

For purposes hereof, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin, “affiliate” shall mean, as applied to any entity, any other entity directly or indirectly controlling, controlled by, or under direct or indirect common control with, such entity (for purposes hereof, “control” (including, with correlative meanings, the terms “controlling,” “controlled by” and “under common control with”), as applied to any entity, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by contract or otherwise), and “person” shall mean any individual, corporation, partnership, limited liability company, trust, joint venture, governmental entity or other unincorporated entity, association or group.

 

 3 

 

 

3.                  Standstill.

 

(a)               Current Holdings. Shareholder hereby represents and warrants that, as of the date hereof, Shareholder does not have, directly or indirectly, beneficial ownership of securities, or rights or options to own, acquire or vote any such securities (through purchase, exchange, conversion or otherwise), of the Company, other than the Retained Shares.

 

(b)              Standstill Restrictions. During the Lock-up Period, except as specifically permitted under an executed definitive agreement entered into between Shareholder and the Company, Shareholder will not, and will cause each of his affiliates and his and their respective representatives and any other agents acting on its or their behalf, or other persons or entities acting in concert with Shareholder or his affiliates, not to, directly or indirectly, (i) make, effect or commence any tender or exchange offer, merger or other business combination involving the Company, (ii) commence or complete, or propose to commence or complete, any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Company, (iii) make, or in any way participate in, any “solicitation” of proxies to vote or consent, or seek to advise or influence any person with respect to the voting of, any securities of the Company (all within the meaning of Section 14 of the Exchange Act), (iv) form, join or in any way participate in a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to, or otherwise act in concert with any person in respect of, any securities of the Company, (v) otherwise act, alone or in concert with others, to seek representation on or to control or influence the management, the Board of Directors of the Company or policies of the Company, (vi) negotiate with or provide any information to any person with respect to, or make any statement or proposal to any person with respect to, or make any public announcement or proposal or offer whatsoever with respect to, or act as a financing source for or otherwise invest in any other persons in connection with, or otherwise solicit, seek or offer to effect any transactions or actions described in the foregoing clauses (i) through (vi), or make any other proposal inconsistent with the terms of this Agreement or that otherwise could reasonably be expected to result in a public announcement regarding any such transactions or actions, (vii) advise, assist, or encourage any other persons in connection with any of the foregoing; or (viii) make any statement or proposal to the Board of Directors of the Company, any of the Company’s representatives or any of the Company’s stockholders regarding, or make any public announcement, proposal or offer, with respect to, or otherwise solicit, seek or offer to effect, any request or proposal to waive, terminate or amend the provisions of this Agreement, unless and until, in the case of each of the foregoing clauses (i) through (viii), Shareholder has received the prior written invitation or approval of the Board of Directors of the Company to do so or the transaction or action falls within the scope of one of the exceptions to the Lock-Up provided for in Section 2 above.

 

4.                  Ownership of Shares; Voting Rights. During the Lock-up Period, Shareholder shall retain all rights of ownership in the Retained Shares, including voting rights and the right to receive any dividends that may be declared in respect thereof and paid in cash or shares of the Company’s common stock (in each case, a “Dividend”). Any shares of the Company’s common stock issued to Shareholder during the Lock-up Period (a) as a Dividend (other than in connection with a stock split, whether effected directly or through a Dividend), or (b) upon reinvestment of a Dividend through the Company’s dividend reinvestment program, shall not be subject to the terms of this Agreement.

 

 4 

 

 

5.                  Miscellaneous.

 

(a)               Further Assurances. From time to time until the expiration of the Lock-up Period, at the Company’s request and without further consideration, Shareholder shall execute and deliver such additional documents and take all such further lawful action as may be necessary or desirable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement.

 

(b)              Specific Performance. Each of the Parties agrees, recognizes and acknowledges that a breach by it of any covenants or agreements contained in this Agreement will cause the other parties to sustain damages for which they would not have an adequate remedy at law for money damages, and therefore each of the Parties agrees that in the event of any such breach any aggrieved Party shall be entitled to the remedy of specific performance of such covenants and agreements (without any requirement to post bond or other security and without having to prove actual damages) and injunctive and other equitable relief in addition to any other remedy to which it may be entitled, at law or in equity.

 

(c)               Remedies Cumulative. All rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or in equity shall be cumulative and not alternative, and the exercise of any such rights, powers or remedies by any Party shall not preclude the simultaneous or later exercise of any other such right, power or remedy by such Party.

 

(d)              Amendment and Modification. No amendment or modification or addition to this Agreement will be valid or effective unless the same is in writing and signed by each of the Parties.

 

(e)               Assignability; Third Party Rights. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; provided, that neither this Agreement nor any of the rights or obligations of any Party hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by any Party without the other Party’s prior written consent shall be void and of no effect. Nothing in this Agreement is intended to or shall confer upon any person (other than the Parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

(f)                Entire Agreement; Counterparts; Exchanges by Facsimile. This Agreement constitutes the entire agreement, and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter of this Agreement, other than the Stock Sale Agreement. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery in .pdf format shall be sufficient to bind the Parties to the terms and provisions of this Agreement.

 

 5 

 

 

(g)               Notices. All notices, demands, consents, requests, instructions and other communications to be given or delivered or permitted under or by reason of the provisions of this Agreement or in connection with the transactions contemplated hereby shall be in writing and shall be deemed to be delivered and received by the intended recipient as follows: (i) if personally delivered, on the business day of such delivery (as evidenced by the receipt of the personal delivery service); (ii) if mailed certified or registered mail return receipt requested, two (2) business days after being mailed; or (iii) if delivered by overnight courier (with all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the overnight courier service of recognized standing). If any notice, demand, consent, request, instruction or other communication cannot be delivered because of a changed address of which no notice was given (in accordance with this Section 4(g), or the refusal to accept the same, the notice, demand, consent, request, instruction or other communication shall be deemed received on the second business day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands, consents, requests, instructions and other communications will be sent to the following addresses or facsimile numbers as applicable:

 

If to the Company to:

 

NeuroOne Medical Technologies Corporation

10901 Red Circle Dr., Suite 150

Minnetonka, Minnesota 55343

Attention: David A. Rosa

     

With copies to:

 

 

 

 

 

If to Shareholder to:

 

 

 

With copies to:

 

Honigman LLP

650 Trade Centre Way, Suite 200

Kalamazoo, Michigan 49002

Attention: Phillip D. Torrence, Esq.

Fax: 269.337.7703

 

Wade Fredrickson

4825 Suburban Drive

Shorewood, Minnesota 55331

 

Nilan Johnson Lewis PA

120 South Sixth Street, Suite 400

Minneapolis, Minnesota 55402

Attention: John C. Levy

Fax: 612.305.7501 

 

Any such person may by notice given in accordance with this Section 4(g) to the other parties hereto designate another address or person for receipt by such person of notices hereunder.

 

(h)              Titles and Captions. All Section titles or captions in this Agreement are for convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions hereof.

 

(i)                 Further Action. The parties shall execute and deliver all documents, provide all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of this Agreement. Each Party shall bear its own expenses in connection therewith.

 

 6 

 

  

(j)                Governing Law; Consent to Jurisdiction, Waiver of Jury Trial. This Agreement will be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its principles of conflicts of laws. Each of the Parties hereto irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Minnesota for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby.  Service of process in connection with any such suit, action or proceeding may be served on each Party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.  Each of the Parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  Each Party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

(k)              Creditors. None of the provisions of this Agreement shall be for the benefit of or enforceable by creditors of any Party.

 

(l)                 Waiver. No failure by any Party to insist upon the strict performance of any covenant, agreement, term or condition of this Agreement or to exercise any right or remedy available upon a breach thereof shall constitute a waiver of any such breach or of such or any other covenant, agreement, term or condition.

 

(m)            Attorney’s Fees. If any dispute arises with respect to the enforcement, interpretation, or application of this Agreement and costs are incurred to resolve such dispute, the prevailing party in such dispute shall recover from the non-prevailing party all costs and expenses, including reasonable attorneys’ fees, incurred by the prevailing party in such dispute.

 

 

Signatures on the Following Page

 

 7 

 

 

In Witness Whereof, the Parties have executed this Agreement as of the Effective Date.

 

Shareholder:   The Company:
     
   

NeuroOne Medical Technologies Corporation 

       
       
/s/ Wade Fredrickson   By: /s/ Dave Rosa
Wade Fredrickson   Name: Dave Rosa
    Title: CEO and President

 

 

 8